Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.

In that head-to-head study (a 30-week, open-label trial that included 295 patients with Type 2 diabetes), patients’ treatment satisfaction was also measured by the DTSQ and, although the results showed a trend towards greater treatment satisfaction with exenatide once weekly vs. twice daily, the difference was not statistically significant [ 7 ].

also in 53,322 other papers